AVIR HCV Pill Matches Epclusa in Phase 3, 8-Week Duration

Atea Pharmaceuticals (AVIR) announced positive topline results from the Phase 3 C-BEYOND trial on July 28, showing its once-daily bemnifosbuvir/ruzasvir combination matched Gilead’s Epclusa in curing hepatitis C. The stock barely moved, closing at $4.82, up 0.4%.

The numbers

• Ticker: AVIR
• Stock price: $4.82 (close July 25, 2026)
• Market cap: $386 million
• Drug: Bemnifosbuvir/ruzasvir (BEM/RZR), a fixed-dose combination of a nucleotide analog polymerase inhibitor and an NS5A inhibitor
• Indication: Chronic hepatitis C virus (HCV), all genotypes
• Trial: C-BEYOND Phase 3 (North America, n=905 treatment-naive patients)
• Primary endpoint: Statistical non-inferiority versus sofosbuvir/velpatasvir (Epclusa) at Week 24

In the modified intent-to-treat population, BEM/RZR achieved 93.9% sustained virologic response (SVR) versus 94.8% for Epclusa, within the prespecified 5% non-inferiority margin. SVR is the accepted definition of a cure for HCV: the virus is undetectable in blood 12 weeks after finishing treatment.

The key differentiator is duration. In patients without cirrhosis, who made up 721 of 905 trial participants, BEM/RZR was administered for just 8 weeks versus 12 weeks for Epclusa. The 8-week arm achieved 93.5% SVR compared to 94.6% for the 12-week comparator. In cirrhotic patients (n=184), both drugs were given for 12 weeks and achieved identical 95.4% SVR rates.

Why the market shrugged

The reaction was muted for good reason. BEM/RZR demonstrated non-inferiority, not superiority. In a mature HCV market dominated by Gilead, matching the standard of care is clinically meaningful but commercially marginal. Gilead has entrenched distribution channels, payer relationships, and brand recognition built over a decade. Atea is a $386 million company with no approved drugs and no commercial infrastructure.

The NDA is still over a year away. Atea needs results from C-FORWARD, the second Phase 3 trial conducted outside North America with more than 880 patients, before filing. C-FORWARD topline results are expected in early 2027. NDA filing would follow, with potential approval in 2028 at the earliest.

The competitive picture

HCV is a clinically solved problem. Gilead’s Epclusa and Mavyret (AbbVie) both cure over 95% of patients across all genotypes. The market has contracted from $24 billion at its peak in 2015 to under $3 billion today as shorter regimens and generic competition compressed pricing. Roughly 80 to 90% of US HCV patients do not have cirrhosis, meaning the 8-week duration advantage applies to the majority, but whether that translates into market share against entrenched competitors is an open question.

Atea’s pitch is differentiation: a shorter 8-week course, low drug-drug interaction risk, and no food effect. Approximately 80% of HCV patients take multiple concomitant medications for comorbidities, so a cleaner drug-interaction profile could matter for prescribers. But these are convenience advantages, not efficacy advantages, and HCV payers reimburse on SVR rates and price.

What to watch

The risk is execution and funding. Atea has no revenue and is burning cash through two Phase 3 trials. The C-FORWARD readout in early 2027 is the next catalyst; if it confirms C-BEYOND results across diverse genotypes, Atea can file. Watch for partnership or licensing deals before then, as a $386 million company will struggle to build a commercial HCV franchise alone. Also watch Gilead’s response: any pricing pressure or label expansion from the incumbent could compress Atea’s already narrow window.

Sources: Atea C-BEYOND press release via BioSpace, C-BEYOND on ClinicalTrials.gov, how to read a clinical trial press release